IDH1 and central nervous system cancer: Inhibitors of mutated IDH1/2 enzymes entered clinical trials and represent a novel drug class for targeted therapy of gliomas. These include AG-881, AG-120, and AG-221, all of which are being tested in preclinical and clinical settings.